Ngl Fine Chem Ltd


Ngl Fine Chem Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,248.40
  • Today's Change-15.00 / -1.18%
  • Shares traded7.82k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Mar 21 2023.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

NGL Fine-Chem Limited is an India-based manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen, Flunixin Meglumine, and Imidocarb Dipropionate, among others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets.

  • Revenue in INR (TTM)2.82bn
  • Net income in INR-817.29m
  • Incorporated1981
  • Employees329.00
  • Location
    Ngl Fine Chem LtdMetalage Indust CompoundSubhash Road, Jogeshwari EastMUMBAI 400057IndiaIND
  • Phone+91 2 240842222
  • Fax+91 2 240539900
  • Websitehttp://www.nglfinechem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Windlas Biotech Ltd4.95bn459.70m5.08bn962.0011.40--8.821.0321.1321.13227.25--------5,140,343.00--------36.09--9.30----50.42----8.96--140.58------
Syncom Formulations India Ltd2.22bn163.62m5.50bn--28.73--26.512.480.20370.20372.65------------7.84--10.4336.1531.247.398.17--4.10-----10.273.51-32.1613.197.588.45
SMS Pharmaceuticals Ltd4.34bn-41.61m5.58bn1.03k----14.871.29-0.4871-0.487151.05--------4,205,091.00--7.71--10.2222.9434.081.2510.04---0.227--5.01-7.693.08-0.49116.913.268.45
Beta Drugs Ltd-100.00bn-100.00bn5.95bn--------------------------------------------------57.91--356.78------
Vimta Labs Ltd3.10bn473.23m6.51bn1.27k14.03--8.502.1020.9920.99137.66--------2,438,790.00--8.88--11.1876.7571.3415.2410.45--21.68--15.8932.0912.5893.0931.30-0.5906--
Panacea Biotec Ltd4.72bn12.17bn6.76bn1.06k0.556--0.55041.43198.47198.4777.11--------4,458,904.00--9.69--17.4643.9855.39257.8524.67---2.27--0.005.833.46837.06---12.14--
Lincoln Pharmaceuticals Ltd5.00bn713.61m6.83bn1.25k9.57--8.531.3735.6235.62249.77------------13.45--17.0852.3750.5514.2613.25--56.07----11.305.2611.4619.7920.914.56
Medico Remedies Ltd-100.00bn-100.00bn6.94bn----------------------------3.41--7.20--24.67--2.43---------1.1217.3388.6824.60-4.35--
Zota Health Care Ltd1.34bn-41.49m7.40bn297.00----134.175.50-1.65-1.6553.61--------4,526,751.00--5.37--7.0536.4830.73-3.094.88---1.62--67.6322.8512.884,364.059.9611.070.9805
Jagsonpal Pharmaceuticals Ltd2.25bn204.13m7.69bn--37.70--35.323.427.797.7985.90------------5.39--6.8560.3658.229.084.60--98.92--38.8515.778.4410.549.71-28.93109.13
NGL Fine-Chem Ltd2.82bn-817.29m7.77bn329.00------2.75-132.29-132.29457.23--------8,580,666.00--17.96--24.1813.7748.76-28.9514.83---63.53--2.9323.0824.42-12.0327.3722.93--
Medicamen Biotech Ltd1.25bn137.00m7.83bn357.0056.22--39.216.2711.0111.01100.53--------3,500,164.00--8.02--11.9751.2233.6610.9710.62--6.12--9.012.426.9622.8223.6229.990.00
Bliss GVS Pharma Ltd7.34bn871.47m7.88bn750.009.22--6.871.078.218.2169.11--------9,784,959.00--7.11--9.8748.3136.8713.1810.68--16.38--11.7929.5012.91-78.04-6.36-6.52-3.58
Bajaj Healthcare Ltd6.91bn569.04m9.08bn1.05k15.96--11.201.3220.6220.62250.20--------6,564,269.00--11.38--19.7026.4725.658.248.64--4.44----3.4924.14-14.1155.6150.96--
Suven Life Sciences Ltd151.49m-1.11bn10.48bn117.00------69.17-6.67-6.670.9369--------1,294,812.00---9.45---10.9276.6465.15-735.49-19.84---360.85-----12.12-53.49-69.08---8.33--
Data as of Mar 21 2023. Currency figures normalised to Ngl Fine Chem Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Motilal Oswal Asset Management Co. Ltd.as of 28 Feb 202315.000.00%
Data from 28 Feb 2023 - 28 Feb 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.